What is the appropriate work‑up and management for a patient presenting with an exanthematous rash, including when to consider hemophagocytic lymphohistiocytosis and treatment options?

Exanthematous Rash: Work-up and Management

In a patient presenting with an exanthematous rash, immediately assess for fever, cytopenias, hepatosplenomegaly, and signs of multiorgan dysfunction—if present with persistent fever unresponsive to standard therapy, initiate HLH screening using HLH-2004 criteria and obtain ferritin, soluble CD25, triglycerides, fibrinogen, and bone marrow examination. 1

When to Suspect HLH

Consider hemophagocytic lymphohistiocytosis (HLH) in any patient with exanthematous rash who presents with:

• Persistent fever (may be masked by antipyretics or renal replacement therapy)
• Rapid clinical deterioration despite appropriate supportive care
• Disproportionate inflammatory response to the clinical picture
• Unexplained cytopenias affecting 2-3 cell lines
• Evolving multiorgan failure
• Unresponsiveness to vasopressors in critically ill patients 1

The combination of fever, generalized rash, bicytopenia, and internal organ involvement after drug exposure is highly predictive of HLH-DRESS overlap 2.

Diagnostic Work-up

Initial Laboratory Screening

Obtain the following tests immediately:

• Ferritin: Levels >10,000 μg/L are >90% sensitive and specific for HLH in children; in adults, ferritin >2,000-6,000 μg/L raises strong suspicion 1
• Soluble CD25 (sIL-2 receptor): ≥2,400 U/mL (superior diagnostic accuracy compared to ferritin, with AUC 0.90) 1
• Triglycerides: ≥3.0 mmol/L (≥265 mg/dL)
• Fibrinogen: ≤1.5 g/L
• Complete blood count: Look for cytopenias in ≥2 lineages (hemoglobin <90 g/L, platelets <100×10⁹/L, neutrophils <1.0×10⁹/L)
• Liver enzymes, LDH, d-dimers
• Bone marrow examination: Essential for identifying hemophagocytosis 1

HLH-2004 Diagnostic Criteria

Diagnosis requires 5 of 8 criteria:

1. Fever
2. Splenomegaly
3. Cytopenias (≥2 lineages)
4. Hypertriglyceridemia and/or hypofibrinogenemia
5. Hemophagocytosis in bone marrow/spleen/lymph nodes
6. Low/absent NK cell activity
7. Ferritin ≥500 μg/L
8. Soluble CD25 ≥2,400 U/mL 1

Alternative Scoring: HScore

Use when HLH-2004 criteria are equivocal. Score >169 suggests 93% probability of HLH. Key weighted parameters include:

• Known immunosuppression (18 points)
• Temperature >39.4°C (49 points)
• Hepatomegaly and splenomegaly (38 points)
• 3 cytopenias (34 points)
• Ferritin >6,000 μg/L (50 points)
• Triglycerides >4 mmol/L (64 points) 1

Identify Underlying Triggers

Critical pitfall: HLH is never a standalone diagnosis—always search for triggers:

• Infections: EBV, CMV, Leishmania, Rickettsia, tuberculosis (obtain viral serologies, blood cultures, TB testing) 1, 3
• Malignancies: Lymphomas (especially T/NK-cell), leukemias (obtain imaging, flow cytometry, lymph node biopsy if indicated) 3
• Rheumatologic conditions: Systemic lupus, Still's disease, systemic JIA (obtain ANA, RF, inflammatory markers) 1
• Drug reactions: DRESS syndrome overlap (review medication history for recent exposures within 2-4 weeks) 2

Treatment Algorithm

Step 1: Immediate Stabilization

• Aggressive critical care support for multiorgan dysfunction
• Frequent reassessment (every 12 hours minimum) 1

Step 2: Treat Specific Triggers FIRST

This is paramount and differs from pediatric protocols:

• Infection-triggered HLH: Start pathogen-specific antimicrobials immediately

  • Leishmaniasis: Liposomal amphotericin B
  • Rickettsial disease: Tetracyclines or chloramphenicol
  • Tuberculosis: Quadruple antibiotic therapy
  • Avoid HLH-94 immunosuppression protocol in infection-triggered cases—these typically respond to antimicrobials alone 1

• Malignancy-triggered HLH: Initiate lymphoma-directed therapy early when feasible 4, 5

• Drug-induced (DRESS-HLH overlap): Discontinue offending agent immediately 2

Step 3: Immunomodulation Based on Subtype

For MAS-HLH (Rheumatologic-Associated):

First-line: High-dose pulse methylprednisolone 1 g/day IV for 3-5 consecutive days 1

Second-line (add if insufficient immediate response):

• Cyclosporine A 2-7 mg/kg/day, OR
• Anakinra (IL-1 blockade) 2-6 mg/kg up to 10 mg/kg/day subcutaneously in divided doses 1

Third-line: Tocilizumab (anti-IL-6) for refractory cases 1

For Severe/Familial HLH or Refractory Secondary HLH:

Do not delay steroid treatment, particularly with organ dysfunction present 6

Add etoposide for:

• Familial HLH
• Severe, persistent, or relapsing secondary HLH
• Malignancy-associated HLH with high inflammatory burden 6, 5

For Critically Ill Patients with MOF:

Consider non-myelosuppressive regimens in patients too unstable for etoposide:

• Anakinra
• Ruxolitinib (JAK1/2 inhibitor)
• IVIG 5, 7

Step 4: Avoid Common Pitfalls

• Do not use HLH-94 immunosuppression in infection-triggered HLH—treat the infection specifically 1
• Do not delay treatment waiting for all diagnostic criteria—start therapy if clinical suspicion is high with evolving organ failure 1, 6
• Do not use steroid monotherapy in patients with viral reactivation—these have poor outcomes 2
• Do not miss drug-induced cases—DRESS-HLH overlap presents average 2.7 weeks after drug exposure, with HLH diagnosis following DRESS by 2.3 weeks 2

Special Considerations

Hyperinflammatory sepsis/MAS-like presentations: These patients may not fulfill full HLH criteria but still require HLH-directed therapy if deteriorating with disproportionate inflammation 1

Bone marrow findings: If initial marrow is non-diagnostic, obtain serial aspirates or biopsy other organs (liver, lymph nodes, spleen). Hemophagocytosis may not be present initially 1

Novel therapies under investigation: Ruxolitinib, emapalumab (anti-IFN-γ), alemtuzumab show promise for refractory cases 1, 7